Analysts’ updated eps estimates for Friday, June 28th:
Adagene (NASDAQ:ADAG) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $5.00 target price on the stock.
Agenus (NASDAQ:AGEN) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $40.00 price target on the stock.
Apellis Pharmaceuticals (NASDAQ:APLS) had its outperform rating reiterated by analysts at Robert W. Baird. Robert W. Baird currently has a $100.00 target price on the stock.
Atossa Therapeutics (NASDAQ:ATOS) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $6.00 target price on the stock.
Banco de Chile (NYSE:BCH) was upgraded by analysts at StockNews.com from a sell rating to a hold rating.
Biogen (NASDAQ:BIIB) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $294.00 target price on the stock.
B&M European Value Retail (LON:BME) had its underweight rating reaffirmed by analysts at JPMorgan Chase & Co..
Bank of Marin Bancorp (NASDAQ:BMRC) had its outperform rating reiterated by analysts at Keefe, Bruyette & Woods. They currently have a $21.00 target price on the stock.
Bunzl (LON:BNZL) had its hold rating reaffirmed by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 3,200 ($40.59) target price on the stock.
Blueprint Medicines (NASDAQ:BPMC) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $130.00 target price on the stock.
Broadridge Financial Solutions (NYSE:BR) had its outperform rating reiterated by analysts at Royal Bank of Canada. The firm currently has a $239.00 target price on the stock.
Chubb (NYSE:CB) had its outperform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $285.00 price target on the stock.
Cincinnati Financial (NASDAQ:CINF) was upgraded by analysts at Citigroup Inc. from a neutral rating to a buy rating. Citigroup Inc. currently has $135.00 price target on the stock, up from their previous price target of $126.00.
CleanSpark (NASDAQ:CLSK) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $27.00 price target on the stock.
Chipotle Mexican Grill (NYSE:CMG) had its outperform rating reissued by analysts at Raymond James. They currently have a $70.00 target price on the stock, up from their previous target price of $67.00.
Corebridge Financial (NYSE:CRBG) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a $33.00 price target on the stock.
Charles River Laboratories International (NYSE:CRL) had its hold rating reiterated by analysts at Argus.
Crinetics Pharmaceuticals (NASDAQ:CRNX) had its buy rating reaffirmed by analysts at HC Wainwright. HC Wainwright currently has a $60.00 price target on the stock.
CRISPR Therapeutics (NASDAQ:CRSP) had its neutral rating reaffirmed by analysts at Guggenheim.
Currys (LON:CURY) had its hold rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a GBX 80 ($1.01) price target on the stock.
Dime Community Bancshares (NASDAQ:DCOM) had its outperform rating reiterated by analysts at Keefe, Bruyette & Woods. The firm currently has a $25.50 target price on the stock.
Digital Realty Trust (NYSE:DLR) was upgraded by analysts at JPMorgan Chase & Co. from a neutral rating to an overweight rating. The firm currently has $175.00 price target on the stock, up from their previous price target of $150.00.
Dynavax Technologies (NASDAQ:DVAX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $29.00 price target on the stock.
Edesa Biotech (NASDAQ:EDSA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $21.00 price target on the stock.
Elevation Oncology (NASDAQ:ELEV) had its market outperform rating reaffirmed by analysts at JMP Securities. The firm currently has a $7.00 target price on the stock.
Eos Energy Enterprises (NASDAQ:EOSE) had its buy rating reaffirmed by analysts at Roth Mkm. Roth Mkm currently has a $4.50 price target on the stock.
Equity Residential (NYSE:EQR) was upgraded by analysts at Piper Sandler from a neutral rating to an overweight rating. They currently have $80.00 price target on the stock, up from their previous price target of $70.00.
Esperion Therapeutics (NASDAQ:ESPR) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $16.00 target price on the stock.
Esperion Therapeutics (NASDAQ:ESPR) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $8.00 price target on the stock.
Essex Property Trust (NYSE:ESS) had its overweight rating reissued by analysts at Piper Sandler. The firm currently has a $315.00 target price on the stock.
EyePoint Pharmaceuticals (NASDAQ:EYPT) had its buy rating reaffirmed by analysts at Chardan Capital. They currently have a $28.00 target price on the stock.
Foresight Group (LON:FSG) had its buy rating reissued by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 600 ($7.61) price target on the stock.
Grupo Financiero Galicia (NASDAQ:GGAL) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Guardant Health (NASDAQ:GH) was upgraded by analysts at Guggenheim from a neutral rating to a buy rating. The firm currently has $36.00 target price on the stock.
Monte Rosa Therapeutics (NASDAQ:GLUE) had its overweight rating reiterated by analysts at Piper Sandler. They currently have a $16.00 target price on the stock.
Global Net Lease (NYSE:GNL) had its outperform rating reissued by analysts at BMO Capital Markets. The firm currently has a $11.00 price target on the stock.
Alphabet (NASDAQ:GOOGL) had its neutral rating reaffirmed by analysts at Rosenblatt Securities. The firm currently has a $181.00 target price on the stock, down from their previous target price of $182.00.
Alphabet (NASDAQ:GOOGL) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $210.00 price target on the stock.
Goosehead Insurance (NASDAQ:GSHD) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $80.00 price target on the stock.
GSK (LON:GSK) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. Deutsche Bank Aktiengesellschaft currently has a GBX 1,950 ($24.74) price target on the stock.
GitLab (NASDAQ:GTLB) had its outperform rating reiterated by analysts at Royal Bank of Canada. They currently have a $65.00 target price on the stock.
The Hartford Financial Services Group (NYSE:HIG) had its sector perform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $105.00 target price on the stock.
Halma (LON:HLMA) had its hold rating reissued by analysts at Deutsche Bank Aktiengesellschaft. They currently have a GBX 2,400 ($30.45) price target on the stock.
Intermediate Capital Group (LON:ICG) had its top pick rating reaffirmed by analysts at Citigroup Inc..
3i Group (LON:III) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co..
Infinera (NASDAQ:INFN) had its hold rating reaffirmed by analysts at Needham & Company LLC.
Samsara (NYSE:IOT) had its buy rating reiterated by analysts at Loop Capital. The firm currently has a $42.00 target price on the stock.
Samsara (NYSE:IOT) had its neutral rating reaffirmed by analysts at Piper Sandler. The firm currently has a $36.00 price target on the stock.
Samsara (NYSE:IOT) had its outperform rating reiterated by analysts at Wolfe Research. Wolfe Research currently has a $44.00 price target on the stock.
Iovance Biotherapeutics (NASDAQ:IOVA) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $32.00 price target on the stock.
Kura Sushi USA (NASDAQ:KRUS) had its buy rating reaffirmed by analysts at Roth Mkm. They currently have a $90.00 target price on the stock, down from their previous target price of $120.00.
Kura Sushi USA (NASDAQ:KRUS) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $115.00 price target on the stock.
Kratos Defense & Security Solutions (NASDAQ:KTOS) had its buy rating reiterated by analysts at Benchmark Co.. Benchmark Co. currently has a $25.00 price target on the stock.
Ligand Pharmaceuticals (NASDAQ:LGND) had its buy rating reaffirmed by analysts at Benchmark Co.. The firm currently has a $95.00 price target on the stock.
LAVA Therapeutics (NASDAQ:LVTX) had its buy rating reiterated by analysts at HC Wainwright. HC Wainwright currently has a $6.00 price target on the stock.
Methanex (NASDAQ:MEOH) (TSE:MX) had its sector perform rating reaffirmed by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $55.00 target price on the stock.
Mirum Pharmaceuticals (NASDAQ:MIRM) had its buy rating reaffirmed by analysts at HC Wainwright. The firm currently has a $66.00 target price on the stock.
Marks and Spencer Group (LON:MKS) had its overweight rating reaffirmed by analysts at JPMorgan Chase & Co..
Marks and Spencer Group (LON:MKS) had its buy rating reiterated by analysts at Deutsche Bank Aktiengesellschaft. The firm currently has a GBX 350 ($4.44) price target on the stock.
Altria Group (NYSE:MO) was upgraded by analysts at StockNews.com from a hold rating to a buy rating.
Moderna (NASDAQ:MRNA) had its hold rating reissued by analysts at Needham & Company LLC.
Merus (NASDAQ:MRUS) had its buy rating reissued by analysts at Needham & Company LLC. The firm currently has a $92.00 target price on the stock.
NIKE (NYSE:NKE) had its sector weight rating reaffirmed by analysts at KeyCorp.
NIKE (NYSE:NKE) had its outperform rating reiterated by analysts at Oppenheimer Holdings Inc.. They currently have a $120.00 target price on the stock.
NIKE (NYSE:NKE) had its hold rating reissued by analysts at Stifel Nicolaus. The firm currently has a $88.00 price target on the stock, down from their previous price target of $117.00.
NIKE (NYSE:NKE) had its equal weight rating reissued by analysts at Morgan Stanley. Morgan Stanley currently has a $79.00 target price on the stock, down from their previous target price of $114.00.
NIKE (NYSE:NKE) had its neutral rating reaffirmed by analysts at UBS Group AG. They currently have a $78.00 target price on the stock.
NIKE (NYSE:NKE) had its neutral rating reissued by analysts at JPMorgan Chase & Co.. The firm currently has a $83.00 target price on the stock, down from their previous target price of $116.00.
NIKE (NYSE:NKE) had its market perform rating reaffirmed by analysts at Raymond James.
Nkarta (NASDAQ:NKTX) had its buy rating reiterated by analysts at Needham & Company LLC. Needham & Company LLC currently has a $13.00 target price on the stock.
Oxford Nanopore Technologies (LON:ONT) had its outperform rating reissued by analysts at Royal Bank of Canada. They currently have a GBX 260 ($3.30) price target on the stock.
Blue Owl Capital (NYSE:OWL) had its overweight rating reiterated by analysts at Piper Sandler. The firm currently has a $23.00 target price on the stock.
Vaxcyte (NASDAQ:PCVX) had its buy rating reissued by analysts at Needham & Company LLC. Needham & Company LLC currently has a $95.00 target price on the stock.
Phathom Pharmaceuticals (NASDAQ:PHAT) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $26.00 price target on the stock.
PayPal (NASDAQ:PYPL) had its outperform rating reiterated by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $84.00 price target on the stock.
R1 RCM (NASDAQ:RCM) had its outperform rating reissued by analysts at Royal Bank of Canada. Royal Bank of Canada currently has a $19.00 price target on the stock.
Sage Therapeutics (NASDAQ:SAGE) had its hold rating reaffirmed by analysts at Needham & Company LLC.
SAP (NYSE:SAP) was upgraded by analysts at BMO Capital Markets from a market perform rating to an outperform rating. They currently have $237.00 target price on the stock, up from their previous target price of $218.00.
J Sainsbury (LON:SBRY) had its underweight rating reissued by analysts at JPMorgan Chase & Co..
Starbucks (NASDAQ:SBUX) had its neutral rating reiterated by analysts at Wedbush. The firm currently has a $81.00 target price on the stock.
SEA (NYSE:SE) had its hold rating reaffirmed by analysts at Dbs Bank. Dbs Bank currently has a $75.00 price target on the stock.
Sagimet Biosciences (NASDAQ:SGMT) had its neutral rating reiterated by analysts at The Goldman Sachs Group, Inc.. The Goldman Sachs Group, Inc. currently has a $6.00 target price on the stock, down from their previous target price of $23.00.
Simply Good Foods (NASDAQ:SMPL) had its buy rating reissued by analysts at Needham & Company LLC. They currently have a $41.00 price target on the stock.
Stoke Therapeutics (NASDAQ:STOK) had its buy rating reiterated by analysts at Needham & Company LLC. The firm currently has a $22.00 price target on the stock.
Travelers Companies (NYSE:TRV) had its market perform rating reissued by analysts at William Blair.
Travelers Companies (NYSE:TRV) had its sell rating reissued by analysts at Citigroup Inc.. The firm currently has a $200.00 price target on the stock, down from their previous price target of $226.00.
Tesco (LON:TSCO) had its underweight rating reaffirmed by analysts at JPMorgan Chase & Co..
Vigil Neuroscience (NASDAQ:VIGL) had its buy rating reiterated by analysts at HC Wainwright. The firm currently has a $24.00 price target on the stock.
Walgreens Boots Alliance (NASDAQ:WBA) had its underperform rating reiterated by analysts at Bank of America Co.. The firm currently has a $11.00 price target on the stock, down from their previous price target of $22.00.
WPP (LON:WPP) had its buy rating reaffirmed by analysts at Citigroup Inc..
Whitestone REIT (NYSE:WSR) had its market outperform rating reiterated by analysts at JMP Securities. They currently have a $15.00 price target on the stock.
X4 Pharmaceuticals (NASDAQ:XFOR) had its buy rating reaffirmed by analysts at HC Wainwright. They currently have a $5.00 target price on the stock.
Receive News & Ratings for Adagene Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adagene Inc and related companies with MarketBeat.com's FREE daily email newsletter.
